Validation Data Gallery
|Positive WB detected in
|HEK-293 cells, HeLa cells, human brain tissue, human testis tissue, Jurkat cells, MCF-7 cells, T-47D cells, MDA-MB-453s cells
|Positive IP detected in
|Positive IHC detected in
|human breast cancer tissue, human testis tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)
|WB : 1:1000-1:4000
|IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
|IHC : 1:300-1:1200
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
10060-1-AP targets FKBPL in WB, IP, IHC, IF, ChIP, ELISA applications and shows reactivity with human samples.
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|FKBPL fusion protein Ag0112
|FK506 binding protein like
|Calculated molecular weight
|349 aa, 38 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
FKBPL, also named as DIR1, NG7 and WISp39, has similarity to the immunophilin protein family, which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking. FKBPL levels may be a prognostic indicator and determinant of response to endocrine therapy(PMID:20103631, 15664193). It can be detected the band between 38 kDa and 48 kDa by western blot.
J Adv Res
Hsa_circ_0001402 alleviates vascular neointimal hyperplasia through a miR-183-5p-dependent regulation of vascular smooth muscle cell proliferation, migration, and autophagy
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
Cell Mol Life Sci
A placenta-on-a-chip model to determine the regulation of FKBPL and galectin-3 in preeclampsia
J Control Release
Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair.
Clin Cancer Res
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.